POLATUZUMAB VEDOTIN
Information current as at: 1 April 2026
The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.
Submission Details
- Brand name:
-
- Polivy®
- Form and strength:
- Please search for and view the medicine's Public Summary Document (PSD) for more information
- Condition/indication:
(therapeutic use) -
- Diffuse large B-cell lymphoma (DLBCL)
- Listing requested:
- Please see PSD for more information
- Funding program:
- Please see PSD for more information
- Request authority level:
- Please see PSD for more information
- PBAC submission type:
- New PBS listing (Standard Re-entry Pathway)
- Comment:
- --
- Submission sponsor:
- ROCHE PRODUCTS PTY LTD
- Other PBAC consideration:
Progress Details
-
Submission received for: - March 2025 PBAC meeting
-
Opportunity for consumer comment: - Open 27/11/2024 and close 29/01/2025 (see PBS Website)
-
PBAC meeting: - Held on 12/03/2025
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
5Lodgement of required documentation:
- Has not yet commenced
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID: a1016
Page last updated: 31 March 2026